CTOs on the Move

CytoDyn

www.cytodyn.com

 
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. We have one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which prevents viral entry into healthy T-cells by blocking the HIV co-receptor CCR5. The drug candidate is also being tested for other immunological conditions, and has been granted FDA orphan drug status for the treatment of Graft versus Host Disease (GvHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cytodyn.com
  • 1111 Main Street Suite 660
    Vancouver, WA USA 98660
  • Phone: 360.980.8524

Executives

Name Title Contact Details
Nitya Ray
Chief Technology Officer Profile

Funding

CytoDyn raised $15M on 03/31/2020

Similar Companies

Princeton Separations Inc

Princeton Separations Inc is a Freehold, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TruSpine Technologies

TruSpine is a medical device company focused on entering the $10.2 billion (US) per annum spinal device market. The Company is developing uniquely disruptive technologies to revolutionise the spinal stabilisation market, commencing with three flagship pioneering, spinal devices. The Cervi-LOK™ (for the cervical and upper thoracic spine), GRASP Laminoplasty (a treatment for decompression of the spinal cord) & Faci-LOK™ (for the lumbar and lower thoracic spine). These unique devices represent a paradigm shift in spinal fixation, by providing exceptional stabilization while not altering the bony anatomy such as screws, staples or other devices which currently dominate the spinal market. The TruSpine philosophy and mantra is one of preserving nature`s design, and as such, the devices have been designed to be safer, faster and easier to implant. The potential cost savings to patients, insurers and surgeons can be significant. The technology is minimally intrusive, minimally invasive and reversable. The first product to market will be Cervi-LOK™, and will be the first posterior cervical stabilisation device in the world which fully preserves the boney anatomy of the spine. TruSpine has a phased product development strategy, and is planning to commence initial product marketing between late 2020 to early 2021. The overall aim is to establish the TruSpine products as the go-to solutions for the spinal stabilisation market. In addition to the three flagship platform products currently under development, the company also has a pipeline of additional and complementary spinal products.

Thrasos Therapeutics

Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease

Aja Labs

Superhuman hair. Engineered from nature.

Deepcell

Our mission is to enable novel biological insights at the single-cell level for improved diagnosis and treatment of disease.